In today’s recent session, 0.5 million shares of the BriaCell Therapeutics Corp (NASDAQ:BCTX) have been traded, and its beta is 1.53. Most recently the company’s share price was $0.53, and it changed around -$0.03 or -4.66% from the last close, which brings the market valuation of the company to $23.42M. BCTX at last check was trading at a discount to its 52-week high of $5.97, offering almost -1026.42% off that amount. The share price’s 52-week low was $0.46, which indicates that the recent value has risen by an impressive 13.21% since then. We note from BriaCell Therapeutics Corp’s average daily trading volume that its 10-day average is 1.26 million shares, with the 3-month average coming to 2.39 million.
BriaCell Therapeutics Corp stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended BCTX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. BriaCell Therapeutics Corp is expected to report earnings per share of 0 for the current quarter.
BriaCell Therapeutics Corp (NASDAQ:BCTX) trade information
Instantly BCTX has been showing red trend so far today with a performance of -4.66% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.5997 on recent trading dayincreased the stock’s daily price by 11.62%. The company’s shares are currently down -90.94% year-to-date, but still down -5.54% over the last five days. On the other hand, BriaCell Therapeutics Corp (NASDAQ:BCTX) is -37.09% down in the 30-day period. We can see from the shorts that 0.69 million shares have been sold at a short interest cover period of 0.77 day(s).
BriaCell Therapeutics Corp (BCTX) estimates and forecasts
BriaCell Therapeutics Corp share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -51.39 percent over the past six months and at a -248.28% annual growth rate that is well below the industry average of 16.70%. Forecasts for the next quarter put sales growth at 0.00%. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 47.85%.
